Table 1 Comparison of characteristics between patients with p-USC and m-USC

Age of diagnosis

64.8 ± 9.1

65.9 ± 8.5

62.7 ± 10.0

0.0953

Age of menopause

51.3 ± 3.39

50.7 ± 3.6

52.4 ± 2.8

0.0217

Time from menopause to diagnosis

13.6 ± 9.4

15.2 ± 8.8

10.4 ± 9.8

0.559

Parity

0.767

 <2

45(49.5%)

29 (48.3%)

16 (51.6%)

 ≥ 2

46(50.5%)

31 (51.7%)

15 (48.4%)

Symptoms

0.861

 Abnormal vaginal bleeding

66(72.5%)

42 (70%)

24 (77.4%)

 Vaginal discharge

5(5.5%)

4 (6.7%)

1 (3.2%)

 Abdominal bloating

7(7.7%)

5 (8.3%)

2 (6.4%)

 others

13(14.3%)

9 (15%)

4 (12.8%)

CA-125(U/ml)

0.644

 normal

51(58.6%)

35 (60.3%)

16 (55.2%)

 elevated

36(41.4%)

23 (39.7%)

13 (44.8%)

 unknown

4

2

2

Surgery approach

0.289

 Complete staging surgery

61(83.6%)

40 (66.7%)

21 (67.7%)

 Cytoreductive surgery

12(16.4%)

10 (16.7%)

2 (6.5%)

 Others

18

10 (16.6%)

8 (25.8%)

FIGO stage

0.174

Stage I total

42(46.2%)

23 (38.3%)

19 (61.3%)

 IA

31(34.1%)

18 (30%)

13 (41.9%)

 IB

11(12.1%)

5 (8.3%)

6 (19.4%)

Stage II

2(2.2%)

1 (1.7%)

1 (3.2%)

Stage III total

33(36.3%)

25 (41.7%)

8 (25.8%)

 IIIA

13(14.3%)

9 (15%)

4 (12.9%)

 IIIB

1(1.1%)

0

1 (3.2%)

 IIIC1

10(11.0%)

8 (13.3%)

2 (6.5%)

 IIIC2

9(9.9%)

8 (13.3%)

1 (3.2%)

Stage IV total

14(15.4%)

11 (18.3)

3 (9.7%)

 IVA

5(5.5%)

3 (5%)

2 (6.5%)

 IVB

9(9.9%)

8 (13.3%)

1 (3.2%)

Adjuvant treatment

0.504

 Chemotherapy

65(84.4%)

43 (86%)

22 (81.5%)

 Chemotherapy and Radiotherapy

9(11.7%)

6 (12%)

3 (11.1%)

None

3(3.9%)

1 (2%)

2 (7.4%)

Unknown

14

10

4

Tumor family history

0.787

 yes

13(14.3%)

9 (15%)

4 (12.9%)

 no

78(85.7%)

51 (85%)

27 (87.1%)

Tumor personal history

0.352

 yes

6(6.6%)

5 (8.3%)

1 (3.2%)

 no

85(93.4%)

55 (91.7%)

30 (96.8%)